Abstract
Purpose
The purpose of this work is to investigate the effect of microenvironmental pH modulation on the in vitro dissolution rate and oral absorption of GDC-0810, an oral anti-cancer drug, in human.
Methods
The pH-solubility profile of GDC-0810 free acid and pHmax of its N-Methyl-D-glucamine (NMG) salt were determined. Precipitation studies were conducted for GDC-0810 NMG salt at different pH values. GDC-0810 200-mg dose NMG salt tablet formulations containing different levels of sodium bicarbonate as the pH modifier were tested for dissolution under the dual pH-dilution scheme. Three tablet formulations were evaluated in human as a part of a relative bioavailability study. A 200-mg dose of GDC-0810 was administered QD with low fat food.
Results
Intrinsic solubility of GDC-0810 free acid was found to be extremely low. The pHmax of the NMG salt suggested a strong tendency for form conversion to the free acid under GI conditions. In vitro dissolution profiles showed that the dissolution rate and extent of GDC-0810 increased with increasing the level of sodium bicarbonate in the formulation. The human PK data showed a similar trend for the geometric mean of Cmax and AUC0-t for formulations containing 5%, 10%, and 15% sodium bicarbonate, but the difference is not statistically significant.
Conclusion
Incorporation of a basic pH modifier, sodium bicarbonate, in GDC-0810 NMG salt tablet formulations enhanced in vitro dissolution rate of GDC-0810 via microenvironmental pH modulation. The human PK data showed no statistically significant difference in drug exposure from tablets containing 5%, 10%, and 15% sodium bicarbonate.
Similar content being viewed by others
Abbreviations
- API:
-
Active pharmaceutical ingredient
- AUC:
-
Area under the curve
- FaSSIF:
-
Fasted-state simulated intestinal fluid
- HPLC:
-
High performance liquid chromatography
- IDR:
-
Intrinsic dissolution rate
- NMG:
-
N-Methyl-D-glucamine
- PXRD:
-
Powder x-ray diffraction
- SGF:
-
Simulated gastric fluid
- ssNMR:
-
Solid-state nuclear magnetic resonance
References
Giliyar C, Fikstad DT, Tyavanagimatt S. Challenges and opportunities in oral delivery of poorly water-soluble drugs. Drug Deliv Technol. 2006;6:57–63.
Taylor LS, Zhang GGZ. Physical chemistry of supersaturated solutions and implications for oral absorption. Adv Drug Deliv Rev. 2016;101:122–42.
Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59:603–16.
Higuchi WI, Mir NA, Parker AP, Hamlin WE. Dissolution kinetics of a weak acid, 1,1-hexamethylene p-tolylsulfonylsemicarbazide, and its sodium salt. J Pharm Sci. 1965;54:8–11.
Serajuddin ATM, Jarowski CI. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts I: phenazopyridine. J Pharm Sci. 1985;74:142–7.
Serajuddin ATM, Jarowski CI. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and their sodium salts II: salicylic acid, theophylline, and benzoic acid. J Pharm Sci. 1985;74:148–54.
Doherty C, York P. Microenvironmental pH control of drug dissolution. Int J Pharm. 1989;50:223–32.
Badawy SIF, Gray D, Zhao F, Sun D, Schuster A, Hussain MA. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389. Pharm Res. 2006;23:989–96.
Tatavarti AS, Hoag SW. Microenvironmental pH modulation based release enhancement of a weakly basic drug from hydrophilic matrices. J Pharm Sci. 2006;95:1459–68.
Bi M, Kyad A, Kiang YH, Alvarez-Nunez F, Alvarez F. Enhancing and sustaining AMG 009 dissolution from a matrix tablet via microenvironmental pH modulation and supersaturation. AAPS PharmSciTech. 2011;12(4):1157–62.
Rao VM, Engh K, Qiu Y. Design of pH-independent controlled release matrix tablets for acidic drugs. Int J Pharm. 2003;252:81–6.
Mahjour M, Kesisoglou F, Cruanes M, Xu W, Zhang D, Maguire TJ, et al. Effect of added alkalizer and surfactant on dissolution and absorption of the potassium salt of a weakly basic poorly water-soluble drug. J Pharm Sci. 2014;103(6):1811–8.
Menning M, Dalziel S. Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound. Mol Pharm. 2013;10:4005–15.
Lai A, Kahraman M, Govek S, Nagasawa J, Bonnefous C, Julien J, et al. Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J Med Chem. 2015;58(12):4888–904.
Wood JH, Syarto JE, Letterman H. Improved holder for intrinsic dissolution rate studies. J Pharm Sci. 1965;54(7):1068.
Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res. 2008;25(7):1663–76.
Gao Y, Carr RA, Spence JK, Wang WW, Turner TM, Lipari JM, et al. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling. Mol Pharm. 2010;7(5):1516–26.
Li Y, Gao P, Shi Y, Zhang GG, Gao Y, Wu J. Formulations of pyrimidinedione derivative compounds. US14058071. 2013.
Ran Y, Yalkowsky SH. Prediction of drug solubility by the general solubility equation (GSE). J Chem Inf Comput Sci. 2001;41:354–7.
Van Den Abeele J, Brouwers J, Mattheus R, Tack J, Augustijins P. Gastrointestinal behavior of weakly acidic BCS class II drugs in man - case study of diclofenac potassium. J Pharm Sci. 2016;105(2):687–96.
Petrakis O, Vertzoni M, Angelou A, Kesisoglou F, Bentz K, Goumas K, et al. Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example. J Pharm Pharmacol. 2015;67(1):56–67.
Lipinski CA, Lombardo F, Dominy BW, Feeny PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
Dill WA, Kazenko A, Wolf LM, Glazko AJ. Studies on 5,5′- diphenylhydantoin (Dilantin) in animals and man. J Pharmacol Exp Ther. 1956;118:270–9.
Serajuddin ATM, Jarowski CI. Influence of pH on release of phenytoin sodium from slow-release dosage forms. J Pharm Sci. 1993;82:306–10.
ATM S, Sheen PC, Mufson D, Bernstein DF, Augustine MA. Preformulation study of a poorly water-soluble drug, α-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: selection of the base form dosage form development. J Pharm Sci. 1986;75:492–6.
Bogardus JB, Blackwood RK. Solubility of doxycycline in aqueous solution. J Pharm Sci. 1979;68:188–94.
Li S, Wong SM, Sethia S, Almoazen H, Joshi YM, Serajuddin ATM. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res. 2005;22:628–35.
Acknowledgments and Disclosures
The authors would like to thank Dr. Po-Chang Chiang, Genentech Inc., for valuable scientific discussion. We would like to acknowledge Dr. Ching-Wei Chang, Genentech Inc., for assistance in statistical analysis.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Hou, H.H., Jia, W., Liu, L. et al. Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid – Case Study of GDC-0810. Pharm Res 35, 37 (2018). https://doi.org/10.1007/s11095-018-2347-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11095-018-2347-z